期刊
BONE MARROW TRANSPLANTATION
卷 51, 期 6, 页码 786-792出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2016.20
关键词
-
资金
- Jazz Pharmaceuticals plc
- Molmed S.p.A
- AstellasPharma Europe Ltd
- Celgene International SARL
- Clinigen Group Ltd
- Gilead Sciences Europe Ltd.
- GlaxoSmithKline plc.
- Hospira Inc.
- Janssen
- Medac Hematology GmbH
- MiltenyiBiotec GmbH
- MSD SharpDohme GmbH
- Neovii Biotech GmbH
- Pfizer Oncology
- Sanofi Oncology
- Takeda Pharmaceuticals
- Therakos Photopheresis
- Alexion
- Amgen Oncology GmbH
- Kiadis Pharma
- Macropharma
- Mundipharma
- Pierre Fabre Medicament
- Terumo BCT
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by 25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据